The University of Chicago Header Logo

Connection

Chuan He to Neoplasms

Back to Details
This is a "connection" page, showing publications Chuan He has written about Neoplasms.
Chuan He
Connection Strength
2.825
Neoplasms
  1. RNA modifications in cancer: from biological insights to therapeutic targets. Bioorg Med Chem. 2026 Jan 01; 132:118432.
    View in: PubMed
    Score: 0.303
  2. N6-methyladenosine reader YTHDF2 in cell state transition and antitumor immunity. RNA. 2025 02 19; 31(3):395-401.
    View in: PubMed
    Score: 0.290
  3. LABS: linear amplification-based bisulfite sequencing for ultrasensitive cancer detection from cell-free DNA. Genome Biol. 2024 06 14; 25(1):157.
    View in: PubMed
    Score: 0.276
  4. YTHDF2/m6 A/NF-?B axis controls anti-tumor immunity by regulating intratumoral Tregs. EMBO J. 2023 08 01; 42(15):e113126.
    View in: PubMed
    Score: 0.258
  5. Advances in targeting RNA modifications for anticancer therapy. Trends Cancer. 2023 07; 9(7):528-542.
    View in: PubMed
    Score: 0.256
  6. Regulation of Gene Expression by N6-methyladenosine in Cancer. Trends Cell Biol. 2019 06; 29(6):487-499.
    View in: PubMed
    Score: 0.192
  7. Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells. Nature. 2019 02; 566(7743):270-274.
    View in: PubMed
    Score: 0.191
  8. Inhibition of human copper trafficking by a small molecule significantly attenuates cancer cell proliferation. Nat Chem. 2015 Dec; 7(12):968-79.
    View in: PubMed
    Score: 0.152
  9. TET family proteins: oxidation activity, interacting molecules, and functions in diseases. Chem Rev. 2015 Mar 25; 115(6):2225-39.
    View in: PubMed
    Score: 0.145
  10. Cancer: Damage prevention targeted. Nature. 2014 Apr 10; 508(7495):191-2.
    View in: PubMed
    Score: 0.136
  11. RNA modification systems as therapeutic targets. Nat Rev Drug Discov. 2026 01; 25(1):59-78.
    View in: PubMed
    Score: 0.075
  12. YTHDFs as radiotherapy checkpoints in tumor immunity. J Exp Med. 2025 Aug 04; 222(8).
    View in: PubMed
    Score: 0.074
  13. The YTHDF proteins display distinct cellular functions on m6A-modified RNA. Trends Biochem Sci. 2024 07; 49(7):611-621.
    View in: PubMed
    Score: 0.068
  14. RNA m6A methylation and MDSCs: Roles and therapeutic implications for radiotherapy. Med. 2023 12 08; 4(12):863-874.
    View in: PubMed
    Score: 0.067
  15. Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity. Nature. 2023 11; 623(7989):1034-1043.
    View in: PubMed
    Score: 0.066
  16. A lncRNA from the FTO locus acts as a suppressor of the m6A writer complex and p53 tumor suppression signaling. Mol Cell. 2023 08 03; 83(15):2692-2708.e7.
    View in: PubMed
    Score: 0.065
  17. YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer Cell. 2023 07 10; 41(7):1294-1308.e8.
    View in: PubMed
    Score: 0.064
  18. Detailed modeling of positive selection improves detection of cancer driver genes. Nat Commun. 2019 07 30; 10(1):3399.
    View in: PubMed
    Score: 0.049
  19. Epitranscriptomic influences on development and disease. Genome Biol. 2017 10 23; 18(1):197.
    View in: PubMed
    Score: 0.044
  20. Radiotherapy induces YTHDF2 in dendritic cells impairing cross-presentation and T cell function. J Exp Med. 2026 01 05; 223(1).
    View in: PubMed
    Score: 0.019
  21. Targeting DTX2/UFD1-mediated FTO degradation to regulate antitumor immunity. Proc Natl Acad Sci U S A. 2024 12 17; 121(51):e2407910121.
    View in: PubMed
    Score: 0.018
  22. Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance. Clin Cancer Res. 2024 Oct 01; 30(19):4450-4463.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.